INM (InMed Pharmaceuticals) Scaled Net Operating Assets: 0.19 (As of Mar. 2026)


INM InMed Pharmaceuticals Inc INM
29 GF Score
Price $1.65
GF Value $0.93
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Scaled Net Operating Assets?

InMed Pharmaceuticals INM -0.61% 29 Scaled Net Operating Assets is 0.19 as of Mar. 2026. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

InMed Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was $3.98 Mil. InMed Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was $1.82 Mil. InMed Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $11.19 Mil. Therefore, InMed Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.19.

InMed Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Scaled Net Operating Assets Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.38 0.28 0.26 0.26

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.33 0.19 0.24 0.19

INM vs SNOA, CVSI, PRFX: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Scaled Net Operating Assets falls into.


INM
29GF Score
InMed Pharmaceuticals Inc INM
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

InMed Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(4.504-1.404)/11.823
=0.26

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=15.58 - 11.076
=4.504

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.146 - 0.306 - 0.436
=1.404

InMed Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(3.975-1.822)/11.191
=0.19

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.134 - 5.159
=3.975

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.242 - 0.031 - 0.389
=1.822

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.19 mean?
InMed Pharmaceuticals (INM) has a Scaled Net Operating Assets of 0.19 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Scaled Net Operating Assets too high?
InMed Pharmaceuticals' current Scaled Net Operating Assets is 0.19. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Scaled Net Operating Assets compare to SNOA and CVSI?
InMed Pharmaceuticals' Scaled Net Operating Assets of 0.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Scaled Net Operating Assets is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Scaled Net Operating Assets is 0.19. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Scaled Net Operating Assets is 0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (INM) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INM:

  • Scaled Net Operating Assets: 0.19
  • GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Other Exchanges MWG:Germany
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for INM

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$0.93
GF Value